Tests low-dose liver radiation with immunotherapy in lung cancer or melanoma
Tests low-dose liver radiation added to immunotherapy in adults with liver-spread lung cancer or melanoma.
Key facts
- Who runs it
- Jordan Kharofa
- Where
- Cincinnati, United StatesSee the site
- Trial code
- Registry title
- Promoting Immunotherapy Efficacy With Low-Dose Liver RT
- Status
- Recruiting
- People taking part
- 21 people, planned
- Started
- 15 Dec 2025
- Expected to end
- 15 Dec 2029
- Type of study
- Interventional
- Treatments tested
- LD-LRT
- Record updated
- 27 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma or non-small cell lung cancer that has spread to the liver and who are getting PD-1 or PD-L1 immunotherapy. It tests adding low-dose liver radiation.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Biopsy-proven non-small cell lung cancer or melanoma, with liver metastases seen on imaging. ECOG performance status 2 or lower (or Karnofsky 60% or higher).
- Earlier treatment
- Must be planning to have standard-care PD-L1 or PD-1 checkpoint immunotherapy during the radiation. Adjuvant immunotherapy within 6 months of enrollment excludes a person.
- Biomarker or test result
- For NSCLC in cohort 1, the driver mutations EGFR, ALK, ROS1 or RET are not allowed.
Main reasons for not taking part
- Adjuvant immunotherapy within 6 months of enrollment
- NSCLC with EGFR, ALK, ROS1 or RET mutation (cohort 1)
- Uncontrolled other illness that makes taking part unreasonably hazardous
- Other cancer that could interfere with the safety or results
- Pregnancy
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age ≥18 years
- ECOG performance status ≤2 (or Karnofsky ≥60%, see Appendix A)
- Patients must have adequate organ and marrow function to receive standard of care immunotherapy and/or chemoimmunotherapy as per the treating medical oncologist
- Must be planning to, and able to, undergo active treatment with PD-L1 or PD-1 checkpoint immunotherapy given per standard care throughout the duration of the RT intervention per their treating physician; Note: Patients may receive other SOC CTLA 4 inhibitors or other SOC chemotherapy/immunotherapy in combination with a SOC PD-L1 or PD-1 checkpoint inhibitor and remain eligible
- Biopsy proven Non-Small Cell Lung Cancer (NSCLC) or Melanoma
- Radiographic evidence of liver metastases
- Women of child-bearing potential and men must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
- Patients must have insurance authorization to proceed with radiotherapy prior to initiation of radiation treatment on study
Who cannot take part
- Patients with prior immunotherapy use in the adjuvant setting for NSCLC or Melanoma are eligible unless the adjuvant immunotherapy was delivered within 6 months of enrollment
- Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen in the opinion of the Investigator
- Pregnant women are excluded from this study considering the use of ionizing radiation
- Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous, in the opinion of the Investigator
- Patients with NSCLC are ineligible for enrollment in cohort 1 if the presence of the following driver mutations are noted: EGFR, ALK, ROS1, RET
Where in United States
- University of Cincinnati Medical CenterCincinnati, United StatesContact: UCCC CTOTaking people
About the trial
What the trial wants to find out
The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.
The group in the trial
- LD-LRTTreatment being tested
Low-dose radiation to the liver the week prior to Cycles 1, 2 and 3 of systemic treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PRIME-LRT: PRomoting IMmunotherapy Efficacy With Low-Dose Liver RT
- Plain-language title
- Tests low-dose liver radiation with immunotherapy in lung cancer or melanomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 February 2026